Unitaid Call for Proposals: Establish viable business models for access to monoclonal antibodies in low- and middle-income countries
Unitaid is pleased to announce this call for proposals aimed at demonstrating feasibility and viability of business models that enable equitable access to monoclonal antibodies (mAbs) in low- and middle-income countries (LMICs). Business models must be designed with the objective of enabling affordable and sufficient supply of mAbs in LMICs, with a priority focus on mAbs for infectious diseases. Specific consideration should be given to regional health priorities and community perspectives.
Scope:
Under this call, Unitaid is soliciting proposals to demonstrate feasibility and viability of business models that enable access to an affordable and sustainable supply of mAbs in LMICs, with a priority focus on mAbs for infectious diseases. Establishing proof-of-concept of such business models is expected to catalyse and expand the supply of mAbs in LMICs and to facilitate uptake of optimized processes that reduce the cost of the production and cost of delivery of mAbs.
Unitaid’s strategic priorities include malaria, HIV and co-infections, tuberculosis, women and children’s health, and responding to global health emergencies. Proposals are expected to balance breadth and depth of analysis by taking a comprehensive view of the potential mAbs market in LMICs across disease priorities, while ensuring sufficient depth of knowledge and analysis in the key disease areas being investigated.
Research areas:
- Analysis of demand
- Analysis of supply models and pilots to demonstrate manufacturability proof of concept
- Define the products for which viable use cases can be established
- Engage with community-based organizations from relevant LMIC regions to ensure their input in analysis of demand, supply, and viable use cases
Read more here.
Application deadline March 1, 2024.
